Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton – 29 May 2015 – The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements.

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

Amy G. Feldman, Ronald J. Sokol, – 27 May 2015 – Watch a video presentation of this article

Anna Hadjihambi, Rajiv Jalan – 27 May 2015 – Watch a video presentation of this article

Josep Marti, Ganesh Gunasekaran, Kishore Iyer, Myron Schwartz – 27 May 2015 – Watch a video presentation of this article

Guadalupe Garcia‐Tsao – 27 May 2015 – Watch a video presentation of this article

Rachel H. Westbrook, Andrew D. Yeoman, Kosh Agarwal, Varuna Aluvihare, John O'Grady, Nigel Heaton, Leonie Penna, Michael A. Heneghan – 26 May 2015 – Reports of pregnancy in liver transplantation (LT) patients have largely favorable outcomes. Concerns remain with regards to maternal and graft risk, optimal immunosuppression (IS), and fetal outcomes. We review all post‐LT pregnancies at our center with regard to the outcomes and safety for the patient, graft, and fetus. A total of 117 conceptions occurred in 79 patients. Median age at conception was 29 years.

Lola M. Reid – 25 May 2015

Rajiv G. Tawar, Che C. Colpitts, Jörg Timm, Tanja Fehm, Michael Roggendorf, Helga Meisel, Nicolas Meyer, François Habersetzer, François‐Loïc Cosset, Thomas Berg, Mirjam B. Zeisel, Thomas F. Baumert – 23 May 2015 – Hepatitis C virus (HCV) causes persistent infection in the majority of infected individuals. The mechanisms of persistence and clearance are only partially understood. Antibodies (Abs) against host cell entry receptors have been shown to inhibit HCV infection in cell culture and animal models.